

Special Issue

Personalized Management of Inflammatory Bowel Diseases

Message from the Guest Editor

The management of inflammatory bowel disease (IBD) is undergoing a rapid transformation. Over the last two decades, the concept of precision medicine has progressively emerged, first in oncology and later expanding towards other immune-mediated diseases.

With molecular profiling, predictive biomarkers, and patient-level characteristics as its cornerstones, precision medicine has redefined therapeutic decision making shifting from empirical treatment algorithms to individualized strategies. In IBD, this approach is now gaining momentum, with predictive biomarkers, innovative diagnostic tools, and patient-specific disease trajectories increasingly guiding therapeutic decisions.

This Special Issue aims to bring together cutting-edge research exploring biomarkers of response, novel imaging modalities, advanced endoscopic and histological assessments, and clinical strategies designed to foster individualized care. We welcome original articles and reviews that will help move IBD care toward truly personalized management.

Guest Editor

Dr. Tommaso Innocenti

Gastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale G. B. Morgagni 50, 50134 Florence, Italy

Deadline for manuscript submissions

30 August 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/255188

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).